Business Wire

NC-KBI-BIOPHARMA

23.7.2024 14:01:30 CEST | Business Wire | Press release

Share
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.

In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.

“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”

He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”

About KBI Biopharma, Inc.

KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.

Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 10:00:00 CEST | Press release

Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo

EchoMark Launches European Operations and Partner Ecosystem19.10.2026 10:00:00 CEST | Press release

In response to growing demand from customers, the company is making its invisible forensic watermarking platform fully available in-region, with GDPR-compliant data residency to deliver leak attribution throughout Europe. EchoMark, the award winning invisible forensic watermarking company that identifies the source of information leaks, often in minutes, today announced the launch of its European operations. The full EchoMark platform is now available with European Union data residency, giving customers the option to run watermarking, administration, and leak investigations entirely on EU-based infrastructure. EchoMark has also entered into a partnership with Nomios, a leading European cybersecurity services provider, to deliver, deploy, and support the platform across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909554797/en/ EchoMark is also investing in the wider European insider risk community. The compa

Sagemcom Unveils Its New-Generation of VSB (Video Soundbox), Now Bringing Home Cinema and Karaoke to Every Living Room, First Deployed by DNA in Finland19.10.2026 10:00:00 CEST | Press release

Sagemcom announces the immediate availability of the new generation of VSB (Video Soundbox). Since its launch, operators around the world have chosen Video Soundbox to offer their customers a 4K set-top box and speakers combined in a single device. Building on this success, Sagemcom introduces its new VSB that takes home entertainment one step further. It is the world’s first set-top box for operators based on Broadcom’s BCM74116 SoC to be deployed. The VSB now offers deeper bass and wider sound spatialization for an even more immersive experience. Thanks to audio designed by Bang & Olufsen and Dolby Atmos, the sound is pure, powerful and multidimensional for all types of content. Dolby Vision brings true colors and sharp pictures. Today, the VSB goes far beyond the traditional TV experience. It can be further enhanced with Wireless Surround Speakers. Available as an option, they extend the sound across the entire room: films and series take on a true cinema dimension, while live sport

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 00:05:00 CEST | Press release

Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibodyBoth investigational therapies are being evaluated in ongoing Phase 3 programsIncyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 20:35:00 CEST | Press release

The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye